Aby J. Mathew Sells 10,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,396,428.48. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $23.63 on Friday. The company has a market capitalization of $1.09 billion, a PE ratio of -16.64 and a beta of 1.88. The company has a 50-day simple moving average of $24.64 and a two-hundred day simple moving average of $21.72. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $26.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08. The firm had revenue of $28.33 million during the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. Research analysts expect that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. HC Wainwright assumed coverage on BioLife Solutions in a report on Monday, September 30th. They set a “buy” rating and a $29.00 price objective on the stock. Craig Hallum increased their price target on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. TD Cowen upped their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. Finally, Northland Securities raised their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently made changes to their positions in the business. 1620 Investment Advisors Inc. acquired a new position in BioLife Solutions during the 2nd quarter valued at about $35,000. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 42,265 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares during the last quarter. Register Financial Advisors LLC acquired a new position in shares of BioLife Solutions during the first quarter valued at about $96,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at approximately $122,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.